Table 3.
Compound | *conc. (%) | TA97a (-S9) | TA98 (+S9) | TA100 (+S9) | TA102 (-S9) |
---|---|---|---|---|---|
L-arginine | 5 | 43.0 ± 0.9a | 22.1 ± 8.4a | 48.6 ± 2.5a | 106.5 ± 1.0a |
2.5 | 57.1 ± 2.0b | 67.4 ± 3.7b | 96.0 ± 1.1b | 116.1 ± 0.7a | |
1 | 84.1 ± 1.8b | 85.3 ± 3.6b | 124.1 ± 2.4c | 119.3 ± 0.6a | |
L-canavanine | 5 | (−) 101.9 ± 3.7a | 25.1 ± 6.7a | 38.9 ± 1.5a | 101.1 ± 0.7a |
2.5 | (−) 120.6 ± 4.5a | 64.8 ± 5.0b | 56.7 ± 2.1b | 116.2 ± 0.4a | |
1 | (−) 138.2 ± 4.1a | 80.1 ± 2.3b | 92.2 ± 1.7c | 125.9 ± 1.0a | |
D-pinitol | 5 | 31.2 ± 8.8a | 26.6 ± 7.3a | 36.1 ± 1.8a | 82.8 ± 3.5a |
2.5 | 79.0 ± 6.8b | 48.8 ± 6.5b | 79.6 ± 1.8b | 109.5 ± 4.6a | |
1 | 143.5 ± 16.6c | 65.0 ± 10.3b | 117.2 ± 3.0b | 115.0 ± 5.3a | |
GABA | 5 | 58.8 ± 3.4a | 14.3 ± 7.9a | 32.9 ± 2.1a | 98.3 ± 1.0a |
2.5 | 61.8 ± 2.5a | 45.8 ± 5.1b | 66.2 ± 2.5b | 113.1 ± 0.9a | |
1 | 61.4 ± 1.4a | 72.5 ± 3.0b | 105.4 ± 1.5c | 116.7 ± 0.4a | |
Positive control | Revertant counts | 9-AA | 2-AAF | AFB1 | CHP |
247 ± 3 | 358 ± 26 | 360 ± 3 | 681 ± 4 |
Inhibition expressed as mean % inhibition ± STD of the positive control. All three mean % inhibitions of the pure compounds where compare at similar dilutions. The mM concentrations of the pure compounds (5%) were as follows: L-arginine [0.28 × 103 mM], L-canavanine [0.26x103mM], D-pinitol [0.25 × 103 mM] and GABA (gamma aminobutyric acid) [0.48x103mM]. *Note that GABA concentration is almost double that of the other three compounds. *This table also shows a dose-response increase of the antimutagenic activity of the compounds, where in most cases the highest concentration’s inhibition is more than double that of the lowest. The negative or minus (−) sign indicated co-mutagenicity of L-canavanine with 9-AA in the absence of S9 activation
Abbreviations: 9-AA 9-aminoacradine, 2-AAF 2-acetamidofluorene, AFB1 aflatoxin B1, CHP cumoyl hydroperoxide